Table 3.
Hazard ratios of features associated with overall survival.
| Select Characteristics | n = 71 n (%)a |
Unadjusted HR (95% CI)**c | Adjusted HR (95% CI)*** | |
|---|---|---|---|---|
|
| ||||
| LVSI | No | 49 (69) | Ref | Ref |
| Yes | 22 (31) | 0.4 (0.05–3.2) | 0.6 (0.1–5.5) | |
| p53 mutationb | No | 16 (23) | Ref | |
| Yes | 16 (23) | 1.2 (0.4–2.8) | ||
| Pelvic lymph nodes assessed | No | 8 (11) | Ref | |
| Yes | 63 (89) | 0.3 (0.06–1.1) | ||
| Assessed > 4 pelvic lymph nodes | No | 20 (28) | Ref | * |
| Yes | 51 (72) | 0.4 (0.1–1.8) | ||
| Assessed > 3 Para-aortic lymph nodes | No | 55 (77) | Ref | * |
| Yes | 16 (23) | 0.2 (0.03–2.1) | ||
| Received adjuvant chemotherapy | No | 28 (39) | Ref | |
| Yes | 43 (61) | 0.6 (0.1–2.4) | ||
| Received 6 cycles of adjuvant chemotherapy | No chemotherapy | 28 (40) | Ref | |
| Chemotherapy (<6 cycles) | 10 (14) | 2.7 (0.6–12.8) | ||
| Chemotherapy (6 cycles) | 32 (45) | 0.1 (0.01–1.3) | ||
| Received 6 cycles of adjuvant chemotherapy | No chemotherapy or <6 cycles | 38 (54) | Ref | Ref |
| 6 cycles of chemotherapy | 32 (45) | 0.1 (0.01–0.7) | 0.1 (0.01–0.8) | |
| >2 co-morbidities | No | 47 (66) | Ref | Ref |
| Yes | 24 (34) | 4.3 (1.0–18.3) | 3.9 (0.8–19.2) | |
| Diabetes | No | 56 (79) | Ref | * |
| Yes | 14 (20) | 1.9 (0.4–9.9) | ||
| Hypertension | No | 32 (46) | Ref | * |
| Yes | 38 (54) | 1.2 (0.3–5.1) | ||
| Renal disease | No | 67 (96) | Ref | * |
| Yes | 3 (4) | 11.6 (2.1–63.4) | ||
| Pulmonary disease | No | 60 (86) | Ref | * |
| Yes | 10 (14) | 3.1 (0.7–13.3) | ||
Not a significant predictor after controlling for other variables.
Univariable model on age, T stage and peritoneal cytology do not converge well or do not yield statistically significant associations.
Multivariable model includes percent of clear cell component as covariate. Received >6 cycles of chemotherapy yields statistically significant HR whether adjusting for percent of clear cell component as continuous or categorical variables.
Percentages may not add up to 100% due to missing data.
Missing data or mutation status not assessed in a subset of cases.
Additionally, age, race, BMI, menopausal status, tobacco use, history of hormone replacement therapy use, history of oral contraceptive use, omental sampling, sentinel lymph node assessment, FIGO stage, type of chemotherapy, receipt of adjuvant radiation therapy, and type of radiation therapy were tested but did not yield statistically significant HRs in univariable models and did not statistically significantly impact adjusted HRs in multivariable models.